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OVERVIEW 
 
 
 
 The purpose of this observational study was to evaluate the efficacy of corneal cross-linking for keratoconus, beginning when the procedure was performed up to a year after the procedure in patients at Greys Hospital in Pietermaritzburg, South Africa between January 2010 and December 2015. 
 
 Keratoconus is a progressive, non-inflammatory ectatic corneal disorder characterised by a progressive corneal thinning that causes irregular astigmatism and decreasing visual acuity. It is often associated with allergic conjunctivitis and seems to also have a degree of familial inheritance. Onset is during the first decade and is progressive until the third decade of life when it often seems to stabilise. Amongst the corneal ectatic diseases it remains the most common cause of debilitating progressive visual impairment during childhood and adulthood. Individuals with keratoconus form a significant proportion of patients for a practitioner specialising in corneal diseases, yet it is a disease in which the pathogenesis is poorly understood and until recently there has been no treatment (apart from corneal transplantation) that could be offered that was curative or capable of slowing the progression of the disease. Collagen cross-linking treatment using riboflavin and UV light was developed in an attempt to address this need and the initial results were promising. 
 
 Charts from a sample of 54  eyes from 49 patients aged between 13 and 35 years with keratoconus treated once with corneal cross-linking, were reviewed from the time of the procedure until 1 year after the procedure or for three consecutive follow-up visits after the procedure. Although less successful than similar studies on Caucasian patients, there was significant stability in the keratometric and pachymetry measurements. The results show that the cross-linking procedure for keratoconus is a useful conservative treatment modality to stop the progression of keratoconus. This also means that the need for corneal graft procedures is significantly reduced. The fairly minimal costs involved in this procedure compared to corneal graft procedures are also an important point to consider. More study is required to elicit whether corneal cross-linking is less successful in African patients than in Caucasians. 
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1 INTRODUCTION 
 
 
 
 
1.1 Literature review 
 
 The cornea is the transparent anterior portion of the fibrous coat of the eye (8). In humans the cornea averages 0.52 mm in thickness at the centre and is about 0.65 mm thick at the periphery (9,10,11). The human cornea traditionally consists of five layers: epithelium, Bowman’s membrane, stroma, Descemet’s membrane and endothelium (9,10,11). The newly discovered Dua’s layer will not be discussed. The stroma makes up approximately 90% of the thickness of the cornea and is the major structural component. The cornea’s strength, shape and transparency can be attributed to the anatomic and metabolic properties of the stroma (9,10). The stroma consists of collagen, glycosaminoglycans, keratocytes and nerves. Two to three percent of the stroma consists of cellular components (keratocytes). Collagen makes up approximately 70% of the dry weight of the cornea. Type I collagen makes up the majority of the collagen in the stroma with types III, IV and VI also being present (10). 
 
 Keratoconus is a well-known ectatic condition of the cornea. Cline et al (6) defined keratoconus as, “a developmental or dystrophic deformity of the cornea in which it becomes cone-shaped due to a thinning and stretching of the tissue in its central area”. It is the most common corneal dystrophy affecting one in 2000 people. It is an ectatic corneal disorder characterised by a progressive corneal thinning that causes irregular astigmatism and decreasing visual acuity (10). It is often associated with allergic conjunctivitis and seems to also have a degree of familial inheritance. It usually manifests itself during puberty, is usually bilateral and is more common in women than men.  
 A clinical description of keratoconus might include the following, a non-inflammatory, bilateral, asymmetric progressive ectasia of the cornea associated with thinning, protrusion and distortion of the cornea (12,13,14). Clinical signs of keratoconus include, Vogt’s striae, Fleischer’s ring, corneal thinning, corneal scarring, increased visibility of corneal nerves, characteristic topographical changes, protrusion and rupture/folding in the area of Descemet’s membrane (13,14,15). 
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Keratoconus has a prevalence of between 50 and 230 people per 100 000 of the population depending on the criteria used to diagnose the condition (7). Its patho-physiology is undetermined, thought to include biochemical, physical and genetic factors and probably the final common pathway for several different disorders (22-24).  Aspects of keratoconus that are perhaps not clear are the clinical characteristics of the condition that are common to a particular keratoconic population of patients. For instance, what is the prevalence of Vogt’s striae in that clinic population? In how many patients is it not possible to get any reliable measurements of refractive state, keratometric or topographical data? How many patients present with corneal scarring? What are the locations of the cones? The answers to the above questions are not obvious. Onset is during the first decade and the disease progresses until the third decade of life when it often stabilises.   The treatment of keratoconus can be subdivided in several entities:  1. Optimizing visual acuity with visual aids; a. Spectacle correction b. Regular contact lens fitting c. Advanced (scleral) contact lens fitting 2. Surgically by using the following methods: a. Intracorneal ring segment implantation b. Phakic toric implant lenses c. Corneal grafting procedure 3. Restoring the clarity of the scarred cornea after corneal scarring;  4. Prevention of disease progression by corneal cross-linking.  Yet, it is a disease where the pathogenesis is poorly understood and until recently there has been no treatment (apart from corneal transplantation) that could be offered that was curative or even capable of slowing the progression of the disease (1). The cross-linking of collagen refers to the ability of collagen fibrils to form strong bonds with adjacent fibrils. In the cornea, collagen cross-linking occurs naturally with aging due to oxidative deamination reactions that take place within the end chains of collagen (28). Collagen cross-linking treatment using riboflavin and UV light was developed in an attempt to address this need, and the initial results were promising. This method of therapeutic cross-linking was developed in Germany by researchers at the University of Dresden; it was later called the Dresden Protocol. The exact mechanism is not known but it is believed that riboflavin causes the release of oxygen radicals that in turn induces an oxidation reaction to create new bonds between the collagen fibrils(2). 
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In a first phase (until 2003) different methods of cross-linking were experimentally compared regarding efficacy and safety. The most promising method of treatment comprised UVA (370 nm) and riboflavin as a photo-mediator and was tested in pilot studies on human eyes with progressive keratoconus. Stromal keratocytes were killed up to 320 microns deep in the stroma but the delicate endothelium appeared unaffected. In 2003, the first results of these pilot studies were published (2). Surprisingly, not only a halt in progression was found, but also in more than half of the eyes treated, a regression towards a more regular shaped cornea took place.                                                                                      So far, very few complications have been reported. Progression in keratometry value of 2D or more (corneal steepening), the need for a new contact lens fit, or, "patient reports of decreasing visual acuity" parameters were used in following and monitoring keratoconus progression referenced in the German study by C. G. Carus (3). The sustained effect of cross-linking as a treatment of keratoconus was proven in the later Siena Eye cross study (4) and again in the Australian study of keratoconus (5) using the three parameters, k–values, visual acuities and pachymetry. 
      
 In a resource-constrained environment such as KwaZulu-Natal, South Africa, corneal cross-linking seemed to be the ideal treatment option to prevent expensive and resource intensive corneal transplantation in keratoconic eyes. The first public facility in KwaZulu-Natal to offer cross-linking was Grey’s Hospital in Pietermaritzburg. The patient profile in the first few years was mostly black African, but with time, Caucasian, Indian and patients of mixed race were all included. This will be the first study to evaluate the effectiveness of corneal cross-linking in keratoconus in this patient group. 
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1.3 Hypothesis 
 
 To prove that the corneal cross-linking procedure is an effective method of treatment in patients with progressive keratoconus. 
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2 PUBLICATION READY MANUSCRIPT   
Abstract 
Background: Keratoconus is a progressive non-inflammatory corneal disorder where the normally spherical corneal structure progressively assumes a cone shape, thereby distorting vision and decreasing the quality of life from a young age. Cross-linking remains the only procedure for keratoconus that can be used to halt the progression of the disease. Greys Hospital is one of the few KwaZulu-Natal government hospitals that offers cross-linking and has shown good results preventing blindness from keratoconus. 
Evaluate: the outcome of corneal cross-linking in Greys Hospital in patients between the ages of 13 and 35 years. 
Setting: Patients from the Greys Hospital clinical records of cross-linking procedures performed for keratoconus. 
Methods: An observational, descriptive quantitative chart review study was conducted on charts for patients who had corneal cross-linking for keratoconus between January 2010 and December 2015. 
Results: A total of 54 eyes from 49 patients were analysed from the records, 2 eyes progressed post cross-linking on both K-max and pachymetry values. 12 eyes showed an increase on K-max readings only and 16 showed progression on pachymetry only. 
Conclusion: The study showed that cross-linking for keratoconus is a safe and effective method of treating progressive keratoconus but seems less effective than in comparative studies done in the first world. 
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Introduction: 
 Keratoconus is an ectatic non-inflammatory corneal disorder characterised by progressive corneal thinning that causes irregular astigmatism and decreasing visual acuity. It is often associated with allergic conjunctivitis and seems to also have a degree of familial inheritance. Onset is during the first decade and it progresses until the third decade of life when it often stabilises. Amongst the corneal ectatic diseases it remains the most common cause of debilitating progressive visual impairment in the childhood and young adult phases of life. 
 
 
 
 Individuals with keratoconus form a significant proportion of patients for an eye practitioner managing corneal diseases. Yet, it is a disease where the pathogenesis is poorly understood and until recently there has been no treatment (apart from corneal transplantation) that could be offered that was curative or even capable of slowing down the progression of the disease (1). Collagen cross-linking treatment using riboflavin and UV light was developed in an attempt to address this need and the initial results were promising (2). 
 
Until 2003, different methods of cross-linking were experimentally compared regarding efficacy and safety. The most promising comprised of UVA (370 nm) and riboflavin as a photo-mediator and was tested in pilot studies on human eyes with progressive keratoconus. Stromal keratocytes were killed up to 320 microns deep in the stroma but the delicate endothelium appeared unaffected. 
 
In 2003, the first results of these pilot studies were published (2). Surprisingly, not only a halt in progression was found, but in more than half of the eyes treated regression toward a more regular shaped cornea occurred. So far, very few complications have been reported. Progression of 2D or more keratometry value (corneal steepening), the need for a new contact lens fit, or “if a patient reports of decreasing visual acuity" were used in following and monitoring keratoconus progression in the German study by C.G. Carus  (3). 
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The sustained effect of cross-linking as a treatment of keratoconus was proven in the later Siena Eye cross study (4) and again in the Australian study of keratoconus (5) using the three parameters; k–values, visual acuities and pachymetry.  Meiri Z et al. [19] did a review and meta-analysis of the efficacy of collagen cross-linking where they found that there was an improvement in Snellen Chat visual acuity of 1 to 2 lines at 3 months or more post corneal collagen cross-linking. They further found some topography parameters also improved by 0.6 – 1 D in 12 to 24 months post collagen cross –linking. Meiri et al. made an interesting discovery of decreased endothelial cell density by 225 cells per square millimetre in the first 3 months and thereafter returned to normal. Corneal thickness was reduced by 10 – 20 nm in the year following corneal cross-linking but not after 12 months. It was then concluded that corneal collagen cross-linking is a safe and effective method for halting the progression of keratoconus, while slightly improving visual acuities.  
 In a resource-constrained environment such as KwaZulu-Natal, South Africa, corneal cross-linking seemed to be an ideal treatment option to prevent expensive and resource intensive corneal transplantation in keratoconic eyes. The first public facility to offer cross-linking in KwaZulu-Natal was Grey’s Hospital in Pietermaritzburg. The patient profile in the first few years was mostly black African but Caucasian, Indian and patients of mixed race were included. This will be the first study to evaluate the effectiveness of corneal cross-linking in keratoconus across the different population groups. In this study, the researcher hopes to show that corneal cross-linking is a safe and effective method of treating keratoconus. 
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Research methods and design 
 Charts from all patients with keratoconus, treated once with corneal cross-linking were reviewed from the time of the procedure up to 1 year after the procedure. The patients were taken from recorded data from the Greys Hospital keratoconus clinic. Each eye was treated as an “individual” and was given a unique study number. Preoperative readings were compared with visits taking place within 180 days (early) of the procedure and visits taking place 180 days after the procedure (late). The reasons for dividing the visits into early and late groups are as follows: 1. Visits for the different patients did not occur at regular intervals. Some patients complete three visits within the first six months then default further follow-up, while others might only come late due to transport and other reasons. 2. The researchers wanted to see the difference between pre-treatment and end-result but also whether further changes occur in this population later than six months after the treatment.  The inclusion criteria included, keratoconic eyes that had received a corneal cross-linking procedure done in Grey’s Hospital, Pietermaritzburg between January 2010 and December 2015.  
 The sample consisted of both males and females between the ages of 13 and 35. 
 The following patients were excluded:  
 
1. Patients who had less than 3 follow up dates since the procedure, irrespective of the time after treatment. 
 
2. Cross-linking done in patients for any other indication other than for keratoconus. 
 3. Ocular or central nervous system disease other than keratoconus which prevents good vision. 
 The study looked at the corneal steepness, keratometry, K-values (D) and pachymetry (µm) as primary outcome indices to determine whether corneal cross-linking improves corneal stability in the profile of patients. 
 
• A pachymetric failure-of-treatment is defined as a loss of at least 25 µm in thickness from baseline thinnest area of the cornea. 
 
• A keratometric failure-of-treatment is defined as a gain of at least 2 dioptres steepening in the K-maximum. 
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 The researchers used the Liu method to determine the optimal cut-points. When looking at the data for prediction the researchers were searching for variables before the corneal cross-linking procedure that could predict treatment failure. The age was tested, pre-treatment keratometry and pre-treatment pachymetry readings using logistic regression. The analysis aimed to predict combination (pachymetry + keratometry) as well as failure-of-treatment of the individual indices (pachymetry fail or keratometry fail separately).  Permission to conduct the study was granted by Greys Hospital, the KwaZulu-Natal Department of Health and the BREC committee in the University of KwaZulu-Natal. BREC permit number – BR489/15  
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Results: 
 54 eyes of 49 patients were found to fulfil the criteria for entrance into the study. 
 Follow-up times in the study cohort were not regular therefore all follow up visits were divided into one of two time frames: < 180 days (early) and > 180 days (late). This also allowed us to get an idea whether stabilisation of the cornea keeps increasing more than six months after the treatment.  The average age in the “early group” of visits was 22.3 years with a standard deviation (SD) of 4.94 years pre-surgery, the average keratometry was 57.1 D (SD= 3.89 D), and average corneal thickness was 425.94 µm, with an average follow-up of 114.19 days. The average post-surgery keratometry was 56.93 dioptre and the pachymetry was 415.06 µm. The Wilcoxon sign rank test shows that there is no difference between these two groups for dioptres (p = 0.582) or pachy (p=0.4367) values pre and post procedure. Only 5 eyes out of 42 showed worsening of dioptre values and 4 out of 36 showed further thinning based on pachymetric values. Of the above eyes that worsened only one eye failed to stabilise on both indices. 
 
 
Variable      Obs     Mean     Std. Dev.      Min     Max 
 
                           .33                             
 
       
age 42 22.14286 5.53733 
 
13 39         
 
     
pred 42 50.1631 3.890907 
 
43.3 58.9       
 
     
prep 42 428.7619 45.59622 
 
304 523       
 
  
follow 42 121.4048 39.70136 
 
31 185    
 
   
postd 42 50.9481 5.035051 
 
43.2 70.95     
 
   
                                                        
 
   
postp 42 415.0714 50.40538 
 
297 498 
 
   
 
 
dchange 42 .7850002 2.925887 
 
-5.100002 12.05   
 
 
pchange 42 -13.69048 46.23349 
 
-160 82   
 
   
 
 
  
 
Figure 1: Summary of population in the group with early follow-up 
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The “late group” had an average age of 21 years at first visit (SD= 4.95 years). Average baseline keratometry was 56.78 D (SD= 5.8 D), and pachymetry was 425 µm. The changes in pachymetry and keratometry post procedure was 11.73µm and the dioptre change was -0.373, both the changes are not significant. (pachy p = 0.0551 and keratometry p = 0.3747)  
 
 
 
   
Figure 2: Summary of population in the group with more than 180 days follow-up 
 
 
 
 
 
 
 
3.2 Failure rates 
 
 An analysis of the failure rate of treatment in the long term group revealed that looking  at the overall failures on this group it was observed that when it comes to keratometry there were  7 eyes  out of  out of 41 that failed and  12  out of 41 eyes continued to progress on pachymetry, only one eye failed on both.  
 
3.2.1 Combination failure 
 Results using age, pre-treatment dioptre and pre-treatment pachymetry readings gave no variables to use as predictors for combined indices failure. For the outcome on dioptre failure only the dioptre baseline value is a statistically significant variable. When looking at the outcome of pachymetry failure on its own, the baseline pachymetry seems to be most important but is not statistically significant. 
                                                                                  
     dchange          41   -.3731707    3.447827       -8.2        9.4
     pchange          41    11.73171    36.00766        -62        109
                                                                      
       plong          41    413.2683    40.88889        331        513
       dlong          41    57.15122    8.566216       47.5       79.8
       dbase          41    56.77805    9.022625       44.6       81.4
       pbase          41         425    42.57229        327        543
         age          41    21.31707    4.951964         13         29
                                                                      
    Variable         Obs        Mean    Std. Dev.       Min        Max
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Fig. 3 ROC prediction curves                                                                           
 
 
 
Fig 4. ROC prediction curves displaying the predictive effect of baseline pachymetry on treatment failure. 
 
 The optimal discrimination point for pachymetry in this study is at 450µm thickness and is the value that best separates the study population into two groups – failure and success. This implies that stability is more likely to occur with an initial corneal thickness of more than 450µm than with thinner corneas. The age of 20.5 years is also a threshold but not nearly as powerful as pachymetry in predicting treatment failure and probably has no significance in clinical practice. The sensitivity at cut-point was determined at 0.44 and the specificity at 0.78.  
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There was overall stability in the keratometry and pachymetry measured between the three time periods. Stabilization or improvement was seen in 28 out of the 36 eyes in the early follow-up group and in 23 out of 41 patients in the late follow-up group. Failures generally occurred in only one of the indices and only one patient had a treatment failure on both thinning and steepening of the cornea.  
Discussion:  The main finding in this study was that only 8 eyes had failed out of the sample group of 36 and 7 eyes out of the 41 who had a longer follow up period. There was no statistical difference of treatment failures between the two groups. In this study, therefore, the cornea did not seem to increase or decrease in stability more than six months after the treatment.  We found that most failures came from the continued thinning of the cornea whilst the dioptres were still steady. This was considered as statistically significant for this study. Of the above numbers only one eye progressed in both the k-max and pachymetry parameters. This was considered statistically significant for the study.  Age did not seem to have a significant contribution in terms of those who seemingly progressed but perhaps that also speaks to the criteria that the patients were only between the ages of 13 and 35 and not falling within the paediatric age bracket.  Chunyu et. al [32] did a meta-analysis where they concluded that cross-linking for keratoconus in patients followed for 1 year showed a statistical significance at 12 months post procedure. In the current study, the above behaviour was seen with a significant stabilisation in K- max and pachymetry values.  
 A study of 23 patients by Wollensak et al. (2) on collagen cross-linking showed that in all treated eyes, the progression of keratoconus was at least stopped. 16 eyes (70%) showed regression of the ectasia with a reduction of the maximal keratometry readings by at least 2 dioptres and improvement of the refractive error by 1.14 dioptres was found. These results are substantially better than the results on the current study population group.  
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In a study done by Hersch and Greenstein (4) the results of cross-linked eyes showed that maximum K-value worsened between baseline and 1 month, followed by improvement between the first and third month and stabilization thereafter. The above phenomena were also observed in the current study aligning with previous findings in studies done on the subject. Similar observations were made by Raiskup-Wolf et al (3) who showed 
that the best corrected visual acuity (BCVA) improved significantly (≥1 line) in 53% of 142 eyes in the first year, 57% of 66 eyes in the second year and 58% of 33 eyes in the third year or remained stable (no lines lost) in 20%, 24% and 29% respectively.  A significant number of the patients seen with keratoconus at Greys Hospital also have allergic conjunctivitis or vernal keratoconjunctivitis as it has been found that there is a proven association between keratoconus and chronic ocular allergies [30]. Amongst the points of concern the researchers speculated whether keratoconus and ocular allergies in the African population give the same outcomes as other populations where there is less ocular allergy involved. In the study researchers suggested that atopy, positive family history and smoking are not independent factors affecting corneal cross-linking outcomes.  The outcome of this study was not as favourable as the other prominent studies although the results were significant enough to support the hypothesis. Poli et. al [31] conducted a study in which they looked at patients who had cross-linking for keratoconus and showed that from 1 month up to 6 years in some patients the results may not be as favourable as one expects. They noted that after 1 year moving towards the 6 year period there was a notable improvement in the patients’ parameters including visual acuity. The above study prompts for a study looking at long term effects of corneal cross-linking on these current patients.  Meiri Z. et al [19] also noted in his study that corneal thickness in some individuals who have had corneal cross as a mode of treatment for keratoconus tend to decrease in thickness up to a period of 24 months but not beyond. This is perhaps the same phenomena observed in the current study, hence a longer period of observation could reveal more on the corneal behaviours post cross-linking.  
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Limitations and strengths  Greys Hospital is the only hospital that offers corneal cross-linking for the Uthungulu district and it is a referral hospital. This study is the first conducted to assess the outcome of cross-linking in patients from the Ethekwini and Uthungulu districts.   Despite many challenges including late referrals, poor transport systems, financial constraints and staff shortages the team at Greys Hospital continues to manage keratoconus to the above mentioned districts. 
 Limitations for this study included having a fairly small sample group with varying dates for follow up, therefore the comparison between them is not as accurate as the researchers desired it to be. Dividing the visits into early and late visits aimed to standardise the data more effectively.  The sample included patients who had cross-linking done using the hypotonic riboflavin solution and there is no indication of how many of these patients were included in the study. All patients, however, had “epi-off” cross-linking, where riboflavin is administered to the cornea after a portion of the epithelium had been removed.  Another limitation is that the data from the patients during the time of consultation and examination was taken by different medical officers that worked in the department at the time, therefore, there is a chance of positional variations on the parameters depending on the skill of the officer. Most data, however was taken directly from the Pentacam equipment which adds a degree of objectivity.  Some patients that had the procedure done had mild to moderate ocular allergies and they were marked during the period of the procedure or collection to see if the presence of ocular allergies made a difference in the outcome of cross-linking in those individuals.  Lack of visual acuities as a measure of the procedure outcome is possibly the biggest limitation of this study since our aim in treating is to preserve/ improve visual function in our patients.   
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Implications and recommendations: 
 Corneal cross-linking for keratoconus is still a safe and valid means of halting progression of the disease. A longer follow up study to determine the behavioural pattern post procedure will reveal more in terms of the outcome.  The threshold of 450µm corneal thickness in predicting stability after treatment is, at least partly, to be expected since thicker corneas should logically be more stable from the outset. It might, however, be prudent when counselling patients about the relative success of corneal cross-linking depending on initial corneal thickness.  This study leaves us with many questions in terms of contributors to the rate of success or failure in the African setting. It would be of interest to look at the effect of ocular allergies and the outcome of cross-linking in the African population as a research topic in the future. The effect of earlier referral, larger age differences, treatment with hypotonic vs. isotonic riboflavin, and “epi-on” corneal cross-linking still require researching in a South African population.  
  
17 
 
Conclusion:  These results show that cross-linking for keratoconus is a useful conservative treatment modality to halt the progression of keratoconus. The need for corneal graft procedures is subsequently significantly reduced. The fairly minimal costs involved in this procedure compared to corneal graft procedures are also an important point to consider. Results in African patients might, however, be poorer than in Caucasian eyes for as yet unknown reasons.  
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 EXECUTIVE SUMMARY 
 
 Statement of purpose: 
 The purpose of this observational study is to understand the 6-month efficacy of corneal cross-linking for keratoconus in patients at Greys Hospital in Pietermaritzburg between January 2010 and December 2015. 
 
 This study is necessary because aims to help health workers understand the process and effect of corneal cross-linking for keratoconus in the South African patient population. Trials on keratoconus have been done mostly in first world countries with Caucasian patients. Data and trials that include South African patient populations and how they respond to this type of treatment is still lacking 
 
 The study will be conducted in the following way: 
 
 I am going to collect the records of patients who have had corneal cross- linking for keratoconus. I will find patients between the ages of 13 and 30. The following data will be collected comparing the values before corneal cross-linking with the 2 consecutive values after the procedure K-values (steepest, flattest and average) Pachymetry 
 
 The output from this project will mainly be for my MMed thesis research. Improved patient care and health care recommendations are the desired products of my study. 
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THE PROTOCOL 
 
 1. DEFINING THE RESEARCH PROBLEM 
 
 Keratoconus is a progressive eye disease in which the normally round cornea thins and begins to bulge into a cone-like shape. This cone shape deflects light as it enters the eye on its way to the light-sensitive retina, causing distorted vision. 
 
 Keratoconus usually starts in the teenage years. It can, however, begin in childhood or in people up to about age 30. It is possible in people aged 40 and older, but this is less common. The changes in the shape of the cornea can happen quickly or may occur over several years. The changes can result in blurred vision, glare and halos at night and the streaking of lights. The changes can stop at any time, or they can continue for decades. There is no way to predict how the condition will progress. In most people who have keratoconus, both eyes are eventually affected, although not always to the same extent. 
 
 Keratoconus is the spontaneous weakening and stretching of the cornea and usually develops in one eye first and then later in the other eye. With severe stretching the back of the cornea can tear, swell and take many months for the swelling to go away. This often results in a large corneal scar. Treatment of early keratoconus is eyeglasses. 
 If eyeglasses do not provide adequate vision, then contact lenses, usually rigid gas permeable contact lenses, may be recommended. Eventually, the cornea can become so thin and scarred that a corneal transplant is required – unless there is a method to stop progression of the disease. 
 
 A treatment called corneal collagen cross-linking is effective to help prevent progression of keratoconus. Performing cross-linking on these corneas can also avoid the change in lifestyle associated with loss of vision, corneal transplant and the limitations thereof. 
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2. LITERATURE OVERVIEW AND 
MOTIVATION  
Background and Literature: 
 Individuals with keratoconus form a significant proportion of patients for a practitioner specialising in corneal diseases. Yet it is a disease where the pathogenesis is poorly understood and until recently, there has been no treatment apart from transplantation that could be offered that was curative or even capable of slowing the progression of the disease. [1] Collagen cross-linking treatment using riboflavin and UV light has been developed to address this need and the initial results are promising. [6] 
 
 During the first phase, (until 2003) different methods of cross-linking were experimentally compared regarding efficacy and safety. As the most promising compromise the use of UVA (370 nm) and riboflavin as a photo mediator was tested in pilot studies on human eyes with progressive keratoconus. In 2003, the first results of such pilot studies were published. Surprisingly, not only a halt in progression was found but in more than half of the eyes treated a progression towards a more regular cornea took place. So far, very few complications have been reported. Keratocytes are killed up to 320 microns deep in the stroma but the delicate endothelium appears unaffected. Worldwide, nine cases of therapy-refractory corneal melting were treated by means of UVA/riboflavin cross-linking and in 8 of the 9 cases the melting process was stopped. 
 
 The sustained effect of cross – linking as a treatment of keratoconus were proven in the Siena Eye cross study[4] and again in the Australian study [5]of keratoconus using the same parameters as k–values and pachymetry. 
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 AIMS AND OBJECTIVES 
 
 AIM 
 To evaluate the outcomes of corneal cross- linking in a public tertiary hospital setting in South Africa. 
 
 OBJECTIVES 
 To study the pre-procedural values of K-readings and pachymetry. 
 To look and compare the post procedural values of the same parameters at 2 consecutive values after the procedure. 
 To prove that the corneal cross-linking procedure is an effective method of treatment in patients with progressive keratoconus. 
 
 4. METHODS 
STUDY DESIGN 
 This study is a descriptive, quantitative chart review project. 
  SETTINGS 
 
 The study will be conducted at Greys Tertiary Hospital in the Ophthalmology clinic. 
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Permission to conduct a study granted by the medical manager at Greys Hospital, an application sent to the KwaZulu-Natal department of Health and the BREC office. 
 
 PARTICIPANT SELECTION 
 
 Source: Outpatients 
 
 Age: Adolescent (13-17 years) and Adult (18 – 35 years) 
 
 Numbers: Indicate the number of participants in each of the above study-groups. 
 
 Adolescent: ±60 Adults: ±40, this number was chosen because the number of patients seen at Greys hospital who had the corneal cross –linking procedure fell into the younger age group. 
 
 There were no control groups for this study.  
 Detail inclusion and exclusion criteria: 
 
 Inclusion: 
 Keratoconic patients who have had the corneal cross-linking procedure done in Grey’s Hospital, Pietermaritzburg. 
 Males and females between the ages of 13 and 35 years. 
 
 Exclusion: 
 Patients who had less than three follow up routine visits post the cross-linking procedure. 
 Cross-linking done for any other indication other than keratoconus. 
 Ocular or central nervous system disease other than keratoconus which prevents good vision. 
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MEASUREMENTS 
 
 K-values: Steepest, flattest and average curvature of the cornea measures in mm radius by Pentacam (the smaller the value the steeper the cornea). 
 Pachymetry (corneal thickness) measured as thinnest point by the Pentacam and/or anterior segment OCT (in microns). 
 
 DATA SELECTION AND STATISTICAL ANALYSIS 
 Data will be entered into SPSS version 21 (Statistical Packages for the Social Sciences) for analysis. A p value <0.05 will be considered as statistically significant. A descriptive statistical analysis of the data (means, standard deviations, ranges, frequencies and percentages, etc.) will initially be conducted. Analysis of Variance (Anova) will be used to assess the changes on the Pentacam and Visual acuity scores. 
 
 SAMPLE  
 Adolescent (13-17 years) and Adult (18 – 30 years) 
 Numbers: Indicate the number of participants in each of the above study-groups. Total number of patients = ±100 (estimation – all treated patients are to be included) adolescent: ±60 Adults: ±40 
 
 This number was chosen because the number of patients seen at Greys hospital who had the corneal cross –linking procedure fell into the younger age group. 
 
 
 
 5. ETHICAL CONSIDERATIONS 
 
 This is a retrospective study which will not include direct contact with the patient. Data will be kept anonymous: no identifying numbers, name or specific birth dates will be included in the final presentation. Data will be linked to the specific patient file by random number assignment and kept separately from the data storage: Raw data as well as the identifying list will be kept in an electronic database, encrypted and stored for five years. After this period the information will be securely destroyed. Results as well as the original patient files will be preserved. 
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 6. BUDGET (including Funding obtained) 
 No additional funding is needed for this study. 
 TIME LINES AND PROJECT MANAGEMENT 
 
 
    Nov.2015 – Dec– Jan.2017 Feb. 2017 March –April 
    Nov. 2016     2017 
          
 Data capture        
          
 Analysis        
          
 Write-up        
          
 Publication        
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Study # Pt. age Visit1  k-flat (D) K-ave (D)  Time Visit2 K-steep k-flat K-ave Pachy Time (months) Visit3 K-steep k-flat K-ave Pachy 
KC - 001 34 05.03.12 42,0 46.5 44.25 397 3 08.06.12 41.7 46.6 44.15 397 8 07.02.13 42.6 47.1 44.9 409 
KC 002 43 07.05.12 48.4 54.6 51.5 403 4 18.09.12 49.4 55.1 52.3 353 2 19.11.12 48.9 55.3 52.0 372 
KC 003 23 11.06.12 50.8 56.5 53.5 379 4 16.10.12 49.5 50.9 50.2 461 12 01.10.13 50.4 53.1 51.7 418 
KC 004 27 23.01.12 48.9 53.4 51.15 398 4 28.05.12 48.3 53.1 50.7 415 4 21.09.12 49.0 53.8 51.4 408 
KC 005 27 23.01.12 48.2 53.0 50.6 405 4 28.05.12 48.1 52.5 50.3 406 4 21.09.12 49.6 51.8 50.7 443 
KC 006 28 23.01.12 48.3 53.4 50.85 436 4 28.05.12 47.0 51.5 49.25 470 5 23.10.12 47.0 50.6 48.8 423 
KC 007 25 09.07.12 61.6 67.6 64.6 327 7 18.02.13 61.1 66.7 63.9 308 6 08.08.14 60.5 68.9 64.7 364 
KC – 008 17 09.07.12 45.4 49.6 47.5 460 5 10.12.12 45.4 49.9 47.65 468 5 06.05.13 45.0 49.5 47.25 473 
KC – 009 18 06.05.13 43.7 46.2 44.95 432 7 13.01.14 45.2 46.9 46.05 414 9 05.10.14 44.6 46.7 45.65 402 
KC – 010 48 13.08.12 51.1 55.2 53.15 418 8 22.04.13 51.4 54.7 53.05 415 6 07.10.13 53.7 56.6 55.15 389 
KC – 011 24 14.09.12 50.9 54.2 52.55 380 6 18.03.13 52.9 56.2 54.55 387 6 22.09.14 55.6 54.2 54.9 361 
KC - 012 13 01.09.14 44.1 46.8 45.45 406 4 27.01.15 44.3 47.1 45.7 407 2 02.03.15 44.5 47.3 45.9 435 
KC - 013 13 01.09.14 44.4 47.3 44.85 398 4 27.01.15 43.3 46.2 44.75 330 2 02.03.15 43.3 46.9 45.1 375 
KC - 014 17 28.10.14 50 52.2 51.1 456 4 02.02.15 50.0 51.7 50.85 440 5 27.07.15 49.8 51.7 50.75 447 
KC - 015 17 28.10.14 46 46.6 46.3 479 4 02.02.15 46.4 47.1 46.75 495 5 27.07.15 45.1 46.6 45.85 460 
KC 016 10 10.11.14 54.2 58.9 56.55 443 1 17.12.14 54.8 57.9 56.35 370 2 26.02.15 56.9 61.2 59.1 422 
KC - 017 10 10.11.14 52.4 56.8 54.6 423 1 17.12.14 52.2 56.0 54.1 399 1 16.01.15 52.7 55.7 54.2 365 
KC - 018 45 26.03.14 51.3 52.5 51.9 456 11 10.02.15 51.7 52.7 52.2 444 3 10.05.15 51.0 52.7 51.9 406 
KC - 019 18 07.04.14 45.4 50.2 47.8 395 8 09.12.14 45.1 50.5 47.8 395 5 17.05.15 45.4 50.1 47.8 381 
KC - 020 37 27.10.14 49.8 52.6 51.2 437 2 17.12.14 49.9 52.9 51.4 428 2 05.02.15 49.3 53.5 51.4 430 
KC - 021 37 27.10.14 47.5 49.3 48.4 450 2 17.12.14 47.3 48.8 48.05 431 2 05.02.15 47.8 49.1 48.45 454 
KC - 022 14 19.05.14 42.5 45.1 43.8 425 7 03.12.14 42.9 44.5 43.7 379 1 25.01.15 42.9 46.1 44.5 432 
KC - 023 14 19.05.14 44.4 55.3 49.9 381 8 26.01.15 42.4 58.6 50.5 378 5 14.06.15 45.0 59.5 52.25 364 
KC - 024 17 28.10.14 46 46.6 46.3 479 4 02.02.15 46.4 47.1 46.75 495 5 27.07.15 45.1 46.6 45.85 460 
KC - 025 17 28.10.14 50 52.2 51.1 456 4 02.02.15 50.0 51.7 50.85 440 5 27.07.15 49.8 51.7 50.75 447 
KC - 026 24 14.09.12 50.9 54.2 52.55 380 6 18.03.13 52.9 56.2 54.55 387 6 22.09.14 55.6 54.2 54.9 361 
KC – 027 17 28.10.14 50.0 52.2 51.1 456 4 02.02.15 50.0 51.7 50.85 440 5 27.07.15 49.8 51.7 50.75 447 
KC – 028 25 21.05.12 49.3 53.7 51.5 415 3 27.08.12 49.6 54.1 51.9 416 9 07.05.13 49.7 53.2 51.5 401 
KC - 029 17 21.05.12 52.8 56.6 54.7 417 6 07.11.13 59.3 59.7 59.5 395 2 28.01.14 59.4 64.7 62.1 400 
KC - 030 17 16.04.12 46.0 47.0 46.5 469 5 25.09.12 45.3 46.9 46.1 418 12 30.09.13 47.0 47.8 47.4 403 
KC - 031 34 05.03.12 42.1 46.9 44.5 416 13 07.02.13 41.9 47.5 44.7 387 10 09.12.13 44.0 49.0 46.5 387 
KC - 032 24 24.03.14 51.1 53.4 52.25 462 1 01.04.14 51.5 52.9 52.2 474 6 21.10.14 50.1 52.3 51.2 401 
KC - 033 19 12.08.13 46.6 65.4 56.0 523 5 27.01.14 49.2 67.9 58.6 367 6 27.7.14 46.4 49.7 40.05 478 
KC - 034 19 12.08.13 45.7 48.8 47.3 488 5 27.01.14 46.2 50.5 48.5 456 6 24.07.14 46.7 50.7 48.7 453 
KC - 035 26 09.03.15 50.1 53.1 51.6 458 1 15.04.15 48.8 52.9 50.9 448 3 13.07.15 49.4 53.4 51.4 420 
KC - 036 31 20.10.12 48.8 50.3 49.5 406 3 07.01.13 47.6 50.0 48.8 417 5 13.06.13 47.0 49.2 48.1 425 
KC 0037 29 21.11.13 50.8 56.6 53.7 353 5 17.04.14 49.5 54.4 52.0 377 4 17.08.14 52.4 54.8 52.4 390 
KC 0038 15 08.07.13 49.2 52.2 50.7 457 4 21.11.13 53.6 65.3 59.2 297 6 22.05.14 49.8 54.3 52.05 390 
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KC 0039  30 15.01.12 41.4 45.2 43.3 462 3 03.04.12 43.7 44.0 43.9 476 1 25.05.12 42.7 43.6 43.2 471 
KC 0040  24 10.09.13 55.7 62.1 58.9 411 1 03.10.13 58.1 62.1 60.1 382 2 12.12.13 62.8 79.1 70.95 306 
KC 0041  14 10.09.13 46.1 51.2 48.7 442 1 03.10.13 49.7 52.4 51.2 403 1 06.11.13 49.2 52.5 50.9 413 
KC 0042  15 17.01.11 42.2 44.6 43.4 487 19 10.07.12 42.2 46.0 44.1 491 37 11.08.15 42.9 48.7 45.8 417 
KC 0043  24 21.05.15 51.9 57.7 54.8 426 2 08.07.15 51.5 57.7 54.62 420 13 08.08.16 49.9 55.4 52.65 470 
KC 0044  27 19.03.15 46.8 47.2 47.0 402 0 19.03.15 47.1 65.1 56.1 448 4 22.07.15 46.2 84.4 65.3 505 
KC 0045 ?  03.02.11 49.6 52.1 50.9 459 0 14.02.11 48.7 52.4 50.6 457 5 18.07.11 49.5 52.2 50.85 449 
KC 0046 ?  03.02.11 44.3 48.3 46.3 471 0 14.02.11 44.8 48.5 46.65 474 5 18.07.11 45.2 47.7 46.45 468 
KC 0047  19 04.12.12 56.4D 60D 58.2D 394 5 30.05.13 58 61.4 59.7 401 8 28.01.14  60 60.9 60.45 388 
KC 0048  16 09.12.13 46.9D 56.5D 51.7D 408 1 07.01.14 45.8 56.9 51.4 397 1 04.02.14 45.9 47.3 46.6 351 
KC 049  26 18.08.14 38.2 48.7 43.5 451 6 02.02.15 48.1 52.1 50.3 457 2 16.04.15 45.2 49.4 47.3 513 
KC 0050  31 28.03.11 53.6 59.6 56.6 406 4 25.07.11 54.2 59.7 56.95 388 9 02.04.12 53.4 58.0 55.7 394 
KC 0051  18 03.10.11 47.2 49.3 48.3 334 5 30.05.11 46.6 48.7 47.65 372 7 16.01.12 47.5 49.8 48.65 356 
KC 052  27 17.01.11 43.6 45.4 44.5 458 3 11.04.11 44 45.5 44.75 453 9 13.12.11 43.8 46.2 45.0 449 
KC 0053  14 30.05.11 39.6 41.7 40.65 475 9 06.02.12 38 43.9 40.95 441 10 06.12.12 41.8 45. 43.6 495 
KC 0054  27 17.01.11 42.2 46.2 44.2 433 3 11.04.11 44.7 48.6 46.65 478 8 13.12.11 42.8 47.4 45.1 419 
KC 0055  29 28.05.13 46.3 49.4 47.9 456 7 19.11.13 47.2 50.5 48.85 426 4 20.03.14 47.1 50.5 48.8 414 
KC 0056  8 24.10.13 55.2 57.0 56.1 320 1 18.11.13 54.7 58.1 56.4 366 2 30.1.14 52.8 57.4 55.1 382 
KC 0057  12 19.08.13 43.2 48.0 45.6 404 2 19.10.13 43.2 48.1 45.65 438 1 19.11.13 45.7 49.6 47.7 398 
KC 0058  48 03.03.14 55.2 57.5 56.4 470 2 26.05.14 53.2 54.6 53.9 464 9 10.02.15 53.3 55.8 54.5 391 
KC 0059  25 10.09.10 41.7 44.2 42.3 443 8 09.05.11 42.2 44.2 43.2 445 9 20.02.12 42.1 45.5 43.8 436 
KC 0060  25 10.09.10 40.0 45.4 42.7 434 8 09.05.11 40.6 45.8 43.2 425 9 20.02.12 40.6 46.1 43.35 423 
KC 061  24 10.09.13 44.1 47.7 45.9 402 12 14.09.14 46.7 49.0 47.9 360 6 19.03.15 47.2 47.7 47.5 347 
KC 062  24 10.09.13 44.5 45.4 44.95 428 12 14.09.14 46.1 47.2 46.7 376 4 15.01.15 46.3 47.6 46.95 398 
KC063  12 24.10.13 54.1 58.0 56.1 358 1 18.11.13 55.8 50.6 53.1 319 2 30.01.14 53.1 50.9 51.7 329 
KC 064  27 14.07.14 50.1 53.9 52D 375 1 22.08.14 47.4 56.1 51.8 377 3 17.11.14 50.5 54.4 52.45 375 
KC 065  20 08.04.13 43.1 46.3 44.7 500 1 15.05.13 41.8 46.7 44.25 501 1 05.06.13 42.3 47.5 44.9 498 
KC 066  23 05.09.11 45.0 53.0 49.0 460 5 06.02.12 44.8 54.6 49.7 403 8 30.10.12  47 51.4 49.2 469 
KC 067  21 26.03.12 52.7 53.9 53.3 416 1 30.04.12 52.8 53.6 53.2 402 4 27.08.12 52.1 53.2 52.7 411 
KC 068  21 30.04.12 48.6D 51.9D 50.3D 471 4 27.08.12 47.4 50.3 48.9 428 1 27.09.12 47.4 50.3 52.9 428 
KC 069  26 09.01.12 42.5 53.0 47.75 422 0 30.01.12 42.4 54.3 48.4 423 4 10.05.12 45.0 57.6 51.2 412 
KC 070  26 09.01.12 46.3 57.4 51.85 419 0 30.01.12 46.6 57.0 51.8 427 4 10.05.12 41.7 53.9 47.8 398 
KC 071  9 15.09.14 46.8 54.4 55.6 366 1 19.10.14 47.0 54.9 50.9 386 3 30.03.15 45.6 54.5 50.05 386 
KC 072  28 16.08.10 47.9 50.0 48.95 386 38 03.10.13 52.4 54.3 53.4 326 3 17.02.14 53.4 55.4 54.4 347 
KC 073  12 24.11.14 57.5 62.3 54.9 358 5 27.04.15 58.1 63.3 60.7 387 1 28.05.15 58.1 63.3 60.7 387 
KC 074  18 04.03.13 56.8 52.8 54.8 373 1 04.04.13 58.7 53.8 56.3 385 16 25.08.14 54.7 57.5 56.1 394 
KC 075  19 22.08.11 52.0 58.4 55.2 410 9 28.05.12 52.3 59.2 55.8 439 9 11.03.13 51.9 53.4 52.7 418 
KC 076  22 28.11.11 42.5 43.8 43.2 543 9 06.08.12 44.0 45.8 44.9 478 13 16.09.13 43.9 45.5 44.7 434 
KC 077  25 28.10.13 47.1 58.4 52.8 389 8 02.06.14 46.4 57.3 51.8 353 10 16.04.15  48 56.3 52.2 372 
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KC 078 39 15.04.13 54.2 55.3 54.7 304 1 16.05.13 49.3 58.7 54.0 299 3 15.08.13 51.4 56.9 54.1 309 
KC 079 19 22.08.11 44.3 51.0 47.7 449 9 28.05.12 44.4 51.5 47.9 449 9 13.02.13 44.6 51.6 48.1 444 
KC 080 18 04.03.13 59.6 54.7 57.2 375 10 09.01.14 61.6 73.1 67.3 331 3 24.04.14 67.1 73.3 70.2 194 
 
 
 
 
 
 
Please note that these 80 are the original data before exclusion criteria were applied. 
Once all relevant individuals were excluded we were left with only 54 data sets. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
34 
 
 
35 
 
 
36 
 
 
Zertifikat
 Certificado 
Certificat
 Certificate 
 
Promouvoir les plus hauts standards éthiques dans la protection des participants à la recherche 
biomédicale Promoting the highest ethical standards in the protection of biomedical research participants 
 
Certificat de formation - Training Certificate   
Ce document atteste que - this document certifies that 
 
Noluthando Pupuma 
 
a complété avec succès - has successfully completed  
Good Clinical Practice (GCP) 
 
du programme de formation TRREE en évaluation éthique de la recherche 
 
of the TRREE training programme in research ethics evaluation  
 
 
 
 
 
 
June 18th, 2015 Professeur Dominique Sprumont  CID : HI3tIH96FF 
 
 Coordinateur TRREE Coordinator 
  
 
 
 
Continuing Education Program Continuing Education Programms GCP training program for investigator recognized by Swissmedic  Programmes de formation continue Programme de formation GCP pour investigateur reconnu par Swissmedic 
 
Programme de Formation continue   
 
 
Ce programme est soutenu par - This program is supported by :  
European and Developing Countries Clinical Trials Partnership (EDCTP) (www.edctp.org) - Swiss National Science Foundation (www.snf.ch) - Canadian Institutes of Health Research (http://www.cihr-irsc.gc.ca/e/2891.html) - 
[REV : 20140328] Swiss Academy of Medical Science (SAMS/ASSM/SAMW) (www.samw.ch) - Commission for Research Partnerships with Developing Countries (www.kfpe.ch) - Université de Neuchâtel (www.unine.ch) 
37 
  
